Flerie Invest, an investment firm, and Tencent led a $67m Series B round in Microbiotica, a biotechnology company, with participation from Cambridge Innovation Capital, IP Group and Seventure Partners. “Microbiotica is a highly innovative UK company operating in the very important field of microbiome biology. Through its bioinformatics platform, it is generating therapeutic treatments targeting immuno-oncology and ulcerative colitis. It has a number of drug development programmes that are progressing to clinical trials. British Patient Capital, through our Future Fund: Breakthrough programme, is proud to support this world-class team as they continue to explore and commercialise this exciting new area of medicine," Judith Hartley, British Patient Capital CEO.